📌 Key Takeaways
- Topic: Ultra Pure Silica: What Purity Level You Need and Which Industries Use It
- Keywords: silica surface area
- Published: 2026-11-20 00:25:03
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Sand for Glass: Iron Content, Grades and Specifications
- Silica OEM: How Private-Label and Custom Silica Manufacturing Works
- 36. Baumgartner A., Planinšek O. Application of commercially available mesoporous silica for drug dissolution enhancement in oral drug delivery. Eur. J. Pharm. Sci. 2021;167:106015. doi: 10.1016/j.ejps.2021.106015. [ DOI ] [ PubMed ] [ Google Scholar ]
- Silicon Oxide Anode (SiOx): How It Works and Its Advantages for Lithium-Ion Batteries
- 8. Ahmed H., Gomte S.S., Prathyusha E., A P., Agrawal M., Alexander A. Biomedical applications of mesoporous silica nanoparticles as a drug delivery carrier. J. Drug Deliv. Sci. Technol. 2022;76:103729. doi: 10.1016/j.jddst.2022.103729. [ DOI ] [ Google Scholar ]
- Quartz CAS 14808-60-7: Identification, Hazards and Regulatory Information
- CMP Slurry Silica: Colloidal vs Fumed Silica for Chemical Mechanical Polishing
- Experiments carried out to investigate the effect of physicochemical properties.
What Is Silica Sol? Composition, Acidic vs Alkaline Types and Industrial Applications
What is silica (SiO₂)?
mica powder
What is the difference between fumed silica and precipitated silica?
silica anti settling agent
What drives silica raw material prices?
silicon dioxide CAS 7631-86-9 MSNs are SiO 2 nanoparticles [ 2 ] with a pore diameter between 2 and 50 nm [ 3, 4 ] and with a total diameter of a maximum of 1 µm. Their use in drug delivery dates to the early 1990s when they were synthesized for various scientific applications [ 5 ]. The material known as mesoporous silica was discovered by Mobil Oil Corporation in 1992 [ 6 ]. Their first drug delivery application was demonstrated in 2001 when MCM-41 silica was used to release ibuprofen [ 7 ]. Since then, MSNs have become an increasingly popular drug delivery system due to their advantageous properties and have been typically recognized as secure (GRAS) by the FDA. Tiny SNPs have been approved for human clinical imaging studies, setting the stage for their use in clinical applications of drug delivery. The number of related research activities is continuously increasing each year, expanding their role in cancer treatment, gene delivery, and oral illness therapy [ 5 ]. Their pore size is located between microporous and macroporous systems. They can be used in diverse shapes (sphere, cube, ellipsoid, rod) and sizes, with different pore sizes and pore structures [ 2, 3, 4, 8, 9, 10 ]. They have a high degree of stability [ 8 ] and a rigid framework, which results in resistance to temperature, pH, enzymatic degradation, and mechanical force [ 4 ]. Thanks to the large number of pores, they have a massive particular surface region (approx. 700-1300 m 2 /g) and pore volume (approx. 0.5-1.5 cm 3 /g), which enables effective adsorption of diverse molecules [ 2, 3, 4, 8, 9, 10 ]. By changing the pore size distribution, the range of adsorbable molecules can be controlled [ 3 ], which also lets separation based on size exclusion, which means selective adsorption of molecules of certain sizes. Depending on the size of the pores, tiny molecules together with high molecular weight proteins can be transported into the pores [ 8 ]. In addition, chemical separation is also possible if the surface of the pores is coated with specific functional groups [ 4 ], which enables the separation of the APIs according to their structure [ 4 ]. Such modifications may include the setting of hydrophilicity/hydrophobicity of the surface, depending on whether the adsorption of hydrophobic or hydrophilic molecules is targeted [ 4 ]. By inserting different functional groups, the surface charge can also be controlled so that certain molecules will bind more efficiently. MSNs have a negative surface charge in biological environments, which promotes the electrostatic adsorption of positively charged APIs in the pores [ 10 ]. Moreover, the biological markers attached to the surface of the nanoparticles enable the drug-carrying system to deliver the API in a tissue-specific manner [ 2, 4, 8, 9, 10 ]. A substantial problem is the premature release of the API from the pores during transport [ 4, 8 ], which can be solved by utilizing gatekeepers that respond to special stimuli and keep the pores closed until the stimulus [ 2, 4, 8 ]. In this way, controlled drug delivery and stimuli-responsive release can be achieved [ 2, 4, 9 ]. The drug release could be triggered by temperature, pH, redox potential, light, enzymes, magnetic field, or different ligands [ 4, 8, 11 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.